Death (fetal, neonatal, or later (up to 2 years' corrected age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to 2 years' corrected age))** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to school age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to school age))** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Time to recovery · children up to 18 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · children up to 12 months old with acute bronchiolitis
It is very uncertain whether magnesium sulphate changes duration of hospital stay compared with hypertonic saline (very low certainty).
1 finding from 1 review
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured at 0 to 24 hoursafter treatment · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured 25 to 48 hoursafter treatment · children up to 12 months old with acute bronchiolitis
It is very uncertain whether magnesium sulphate changes clinical severity score (CSS) (RDAI score; range 0 to 17; higher =… compared with hypertonic saline (very low certainty).
1 finding from 1 review